Targeting of iNOS with antisense DNA plasmid reduces cytokine-induced inhibition of osteoblastic activity

American Journal of Physiology - Endocrinology and Metabolism

Volumn 285, Issue 3 48-3, 2003, Pages

  Abe, Takahiro ^a   Hikiji, Hisako ^a   Shin, Wee Soo ^a   Koshikiya, Noboru ^a   Shima, Sei Ichi ^a   Nakata, Jumi ^a   Susami, Takafumi ^a   Takato, Tsuyoshi ^a   Toyo Oka, Teruhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Antisense; Inducible nitric oxide synthase; Osteoblast; Peroxynitrite

Indexed keywords

ALKALINE PHOSPHATASE; COLLAGEN TYPE 1; COMPLEMENTARY DNA; CORE BINDING FACTOR; CYTOKINE; DNA; INTERLEUKIN 1BETA; MESSENGER RNA; NITRIC OXIDE SYNTHASE; OSTEOCALCIN; PEROXYNITRITE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL ACTIVITY; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE IDENTIFICATION; GENE TARGETING; GENETIC TRANSCRIPTION; INFLAMMATION; METABOLITE; NONHUMAN; OSTEOBLAST; PLASMID; PRIORITY JOURNAL;

EID: 0041464576     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00267.2002     Document Type: Article

References (44)

1. Armour KE, Armour KJ, Gallagher ME, Godeche A, Helfrich MH, Reid DM, and Ralston SH. Defective bone formation and anabolic response to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide synthase. Endocrinology 142: 760-766, 2001.
2. Armour KE, van't Hof RJ, Grabowski PS, Reid DM, and Ralston SH. Evidence for a pathogenic role of nitric oxide in inflammation-induced osteoporosis. J Bone Miner Res 14: 2137-2142, 1999.
3. Armour KJ, Armour KE, van't Hof RJ, Reid DM, Wei XQ, Liew FY, and Ralston SH. Activation of the inducible nitric oxide synthase pathway contributes to inflammation-induced osteoporosis by suppressing bone formation and causing osteoblast apoptosis. Arthritis Rheum 44: 2790-2796, 2001.
4. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, and Mundy GR. Stimulation of bone resorption and inhibition in vitro. Nature 319: 516-518, 1986.
5. G-monomethyl-L-arginine uptake: a mechanism for differential inhibition of NO synthase. Am J Physiol Cell Physiol 269: C750-C756, 1995.
6. Brandi ML, Hukkanen M, Umeda T, Moradi-Bidhendi N, Bianchi S, Gross SS, and Polak JM. Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms. Proc Natl Acad Sci USA 92: 2954-2958, 1995.
7. Cartwright JE, Johnstone AP, and Whitley GS. Inhibition of nitric oxide synthase by antisense techniques: investigations of the roles of NO produced by murine macrophage. Br J Pharmacol 120: 146-152, 1997.
8. Cartwright JE, Johnstone AP, and Whitley GS. Endogenously produced nitric oxide inhibits endothelial cell lines. Br J Pharmacol 131: 131-137, 2000.
9. Crow JP and Ischiropoulos S. Detection and quantitation of nitrotyrosine residues in proteins: in vitro marker of peroxynitrite. Methods Enzymol 269: 185-194, 1996.
10. Damoulis PD and Hauschka PV. Cytokines induce nitric oxide production in mouse osteoblasts. Biochem Biophys Res Commun 201: 924-931, 1994.
11. Da Rocha FAC and de Brum-Fernandes AJ. Evidence that peroxynitrite affects human osteoblast proliferation and differentiation. J Bone Miner Res 17: 434-442, 2002.
12. Dawson TM, Bredt DS, Fotuhi M, Hwang PM, and Snyder SH. Nitric oxide synthase and neuronal NADPH diaphorase are identical in brain and peripheral tissues. Proc Natl Acad Sci USA 88: 7797-7801, 1991.
13. Deodhar AA and Woolf AD. Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol 35: 309-322, 1996.
14. 2 in the inhibition of osteocalcin synthesis by human osteoblast-like calls in response to cytokines and systemic hormones. Biochem Biophys Res Commun 167: 194-202, 1990.
15. Farrell AJ, Blake DR, Palmer RM, and Moncada S. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis 51: 1219-1222, 1992.
16. Garvey EP, Oplinger JA, Furfine ES, Kiff RJ, Laszlo F, Whittle BJ, and Knowles RG. 1400 W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. J Biol Chem 272: 4959-4963, 1997.
17. Gewirtz AM, Stein CA, and Glazer PM. Facilitating oligonucleotide delivery: helping antisense deliver on its promise. Proc Natl Acad Sci USA 93: 3161-3163, 1996.
18. Grabowski PS, England AJ, Dykhuizen R, Copland M, Benjamin N, Reid DM, and Ralston SH. Elevated nitric oxide production in rheumatoid arthritis. Arthritis Rheum 39: 643-647, 1996.
19. 15N]nitrate in biological fluids. Anal Biochem 126: 131-138, 1982.
20. Hikiji H, Shin WS, Koizumi T, Takato T, Susami T, Koizumi Y, Okai-Matsuo Y, and Toyo-oka T. Peroxynitrite production by TNF-α and IL-1β: implication for suppression of osteoblastic differentiation. Am J Physiol Endocrinol Metab 278: E1031-E1037, 2000.
21. Hikiji H, Shin WS, Oida S, Takato T, Koizumi T, and Toyo-oka T. Direct action of nitric oxide on osteoblastic differentiation. FEBS Lett 410: 238-242, 1997.
22. Hilliquin P, Borderie D, Hernvann A, Menkes CJ, and Ekindjian O. Detection of nitric-oxide complexed in s-nitroso-proteins in rheumatoid-arthritis (ra) (Abstract). Arthritis Rheum 39: 320, 1996.
23. Hoque AM, Papapetropoulos A, Venema RC, Catravas JD, and Fuchs L. Effects of antisense oligonucleotide to iNOS on hemodynamic and vascular changes induced by LPS. Am J Physiol Heart Circ Physiol 275: H1078-H1083, 1998.
24. Hukkanen M, Hughes FJ, Buttery LDK, Gross SS, Evans TJ, Seddon S, Riveros-Moreno V, Macintyre I, and Polak JM. Cytokine-stimulated expression of inducible nitric oxide synthase by mouse, rat, human osteoblast-like cells and its functional role in osteoblast metabolic activity. Endocrinology 136: 5445-5453, 1995.
25. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, and Klinman DM. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549, 1995.
26. Kr Ncke K, Suschek CV, and Kolb-Bachofen V. Implications of inducible nitric oxide synthase expression and enzyme activity. Antiox Redox Signal 2: 585-605, 2000.
27. Lader CS and Flanagan AM. Prostaglandin E, interleukin 1α and bone resorption in vitro. Endocrinology 139: 3157-3164, 1998.
28. Lewis JG, Lin K, Kothavale A, Flanagan WM, Matteucci MD, DePrince RBB, Mook RA, Hendren RW, and Wagner RW. A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc Natl Acad Sci USA 93: 3176-3181, 1996.
29. Lewis RS, Tamir S, Tannenbaum SR, and Deen WM. Kinetic analysis of the fate of nitric oxide synthesizied by macrophages in vitro. J Biol Chem 270: 29350-29355, 1995.
30. Löwik CWGM, Nibbering PH, Ruit M, and Papapoulos SE. Inducible production of nitric oxide in osteoblast-like cells and in fatal mouse bone explants is associated with suppression of osteoclastic bone resorption. J Clin Invest 93: 1465-1472, 1994.
31. Lyons CR, Orloff GJ, and Cunningham JM. Molecular cloning and functional expression of an inducible nitric oxide synthase from a murine macrophage cell line. J Biol Chem 267: 6370-6374, 1992.
32. MacIntyre I, Zaidi M, Alam ASMT, Datta HK, Moonga BS, Lidbury PS, Hecker M, and Vane J. Osteoclastic inhibition of nitric oxide not mediated by cyclic GMP. Proc Natl Acad Sci USA 88: 2936-2940, 1991.
33. McDonald KK, Zharikov S, Block ER, and Kilberg MS. A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the "Arginine paradox." J Biol Chem 272: 31213-31216, 1997.
34. Moncada S, Palmer RMJ, and Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 43: 109-142, 1991.
35. Palmer RMJ, Ferrige AG, and Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327: 524-526, 1987.
36. Ralston SH, Ho LP, Helfrich MH, Grabowski PS, Johnston PW, and Benjamin N. Nitric oxide: a cytokine-induced regulator of bone resorption. J Bone Miner Res 10: 1040-1049, 1995.
37. Rothe H, Bosse G, Fischer HG, and Kolb H. Generation and characterization of inducible nitric oxide synthase deficient macrophage cell lines. Biol Chem Hoppe-Seyler 377: 227-231, 1996.
38. Stein CA and Cheng YC. Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science 261: 1004-1012, 1993.
39. Taichman RS and Hauschka PV. Effects of interleukin-1β and tumor necrosis factor-α on-osteoblastic expression of osteocalcin and mineralized extracellular matrix in vitro. Inflammation 16: 587-601, 1992.
40. Van't Hof RJ, Armour KJ, Smith LM, Armour KE, Wei XQ, Liew FY, and Ralston SH. Requirement of the inducible nitric oxide synthase pathway for IL-1-induced osteoclastic bone resorption. Proc Natl Acad Sci USA 97: 7993-7998, 2000.
41. Van't Hof RJ and Ralston SH. Nitric oxide and bone. Immunology 103: 255-261, 2001.
42. Wagner RW and Stein CA. The state of the art in antisense research. Nat Med 1: 1116-1121, 1995.
43. Weinreb M, Shinar D, and Rodan GA. Different pattern of alkaline phosphatase, osteopontin, and osteocalcin expression in developing rat bone visualized by in situ hybridization. J Bone Miner Res 5: 831-842, 1990.
44. White CR, Brock TA, Chang L, Crapo J, Briscoe P, Ku D, Bradly WA, Gianturco SH, Gore J, Freeman BA, and Tarpey MM, Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci USA 91: 1044-1048, 1994.